All In Biotech

Drug Trial Radar · NCT04279314

Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome

A 40-Week, Open-label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome

Last checked: Nov 19, 2026Latest source record: Apr 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

154

Actual

Start

Jan 29, 2020

Primary completion

Aug 19, 2022

Study completion Aug 19, 2022

Sponsor

Lead sponsor
ACADIA Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Feb 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 5 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigate the safety and tolerability of long-term treatment with oral trofinetide in girls and women with Rett syndrome

Conditions

  • Rett Syndrome

Interventions

  • TrofinetideDrug

    Trofinetide solution of 30-60 mL based on subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With Treatment-emergent Adverse Events (TEAEs), Percentage of Subjects With Serious Adverse Events (SAEs), and Percentage of Subjects With Withdrawals Due to AEsTime frame: 40 Weeks Treatment Duration
  2. Subjects (N, %) With Post-baseline Potentially Clinically Important Changes in ECGTime frame: 40 Weeks Treatment Duration
  3. Subjects (N, %) With Post-baseline Potentially Clinically Important Changes in Vital SignsTime frame: 40 Weeks Treatment Duration
  4. Subjects (N, %) With Post-baseline Potentially Clinically Important Changes in Body WeightTime frame: 40 Weeks Treatment Duration
  5. Subjects (N, %) With Post-baseline Potentially Clinically Important ChangesTime frame: 40 Weeks Treatment Duration

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Translational Genomics Research Institute (TGen)

    Phoenix, Arizona

  • University of California, San Diego

    La Jolla, California

  • UC Davis MIND Institute

    Sacramento, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Children Medical Services

    Tampa, Florida

  • Emory Genetics Clinical Trial Center

    Atlanta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • Kennedy Krieger Institute - Clinical Trials Unit

    Baltimore, Maryland

  • Boston Children's Hospital

    Boston, Massachusetts

  • Gillette Children's Specialty Healthcare

    Saint Paul, Minnesota

  • Washington University School of Medicine, St. Louis Children's Hospital

    St Louis, Missouri

  • Montefiore Medical Center, Children's Hospital at Montefiore

    The Bronx, New York

  • The University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Greenwood Genetic Center

    Greenwood, South Carolina

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Texas Children's Hospital

    Houston, Texas

  • Seattle Children's

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.